PCSK9 and coronary artery disorder: For example, two nonsense mutations of PCSK9 first reported in humans were found in an African‐American population and associated with a substantial reduction of low‐density lipoprotein cholesterol.[73] This finding demonstrated that a lifelong inhibition of PCSK9 protected against coronary heart disease without noticeable safety issues.